J Med Microbiol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by da Silva Telles, M. A.
Right arrow Articles by Riley, L. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by da Silva Telles, M. A.
Right arrow Articles by Riley, L. W
Agricola
Right arrow Articles by da Silva Telles, M. A.
Right arrow Articles by Riley, L. W
J Med Microbiol 54 (2005), 975-979; DOI: 10.1099/jmm.0.45965-0
© 2005 Society for General Microbiology
ISSN 0022-2615

Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates

Maria Alice da Silva Telles1, Erica Chimara1, Lucilaine Ferrazoli1 and Lee W Riley2

1Instituto Adolfo Lutz, Sao Paulo, Av. Dr. Arnaldo, 355, Sao Paulo, SP 01246-902, Brazil 2School of Public Health, University of California, Berkeley, CA, USA

Correspondence Maria Alice da Silva Telles atelles{at}ial.sp.gov.br

Received November 23, 2004
Accepted May 12, 2005

Mycobacterium kansasii is the second most common cause of non-tuberculosis mycobacterial diseases in Sao Paulo, Brazil. An important component of the management of infections caused by this organism is antibiotic susceptibility testing. The objective of this study was to determine the drug susceptibility profiles and genotypes of clinical isolates of M. kansasii obtained from patients with or without an infection that met the American Thoracic Society's case definition criteria of M. kansasii disease. One hundred and sixty-nine clinical isolates of M. kansasii collected between 1993 and 1998 in Sao Paulo, Brazil, were tested consecutively. The isolates were genotyped by PCR restriction-enzyme pattern analysis (PRA). Most of the M. kansasii strains were susceptible to isoniazid, streptomycin, rifabutin, rifampicin, clarithromycin, ethionamide, amikacin, clofazimine and cycloserine, and resistant to ethambutol, ciprofloxacin and doxycycline. Of 169 isolates, 167 belonged to the type I PRA genotype and one each belonged to type II and III genotypes. There was no correlation between PRA subtype and M. kansasii disease according to the American Thoracic Society case definition. Clinical trials may be needed to better correlate MIC values with treatment outcomes to identify appropriate parameters for drug-resistance testing of M. kansasii.

Abbreviations: AMK, amikacin; ATS, American Thoracic Society; CIP, ciprofloxacin; CLO, clofazimine; CLR, clarithromycin; CS, cycloserine; DOX, doxycycline; EMB, ethambutol; ETH, ethionamide; HIV, human immunodeficiency virus; INH, isoniazid; NTM, non-tuberculosis mycobacteria; PRA, PCR restriction-enzyme pattern analysis; RFB, rifabutin; RIF, rifampicin; SPT, streptomycin.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2005 Society for General Microbiology.